Leading biotech and healthcare venture firm Third Rock Ventures and BrightEdge LLC, the venture arm of the American Cancer Society (ACS), will collaborate for investing in early-stage startups focused on cancer treatments. BrightEdge will therefore get to participate in the the Series A and follow-on financing rounds of such companies as are backed by Third Rock.